Talazoparib in BRCA-mutated advanced breast cancer: is earlier better?

Pharmacogenomics. 2022 Jun;23(8):487-492. doi: 10.2217/pgs-2022-0011. Epub 2022 May 24.

Abstract

Talazoparib is an oral PARP inhibitor approved for locally advanced/metastatic breast cancer. There is no consensus, however, as to whether it is better used as a first-line treatment or after other therapies in patients with gBRCA mutations. In fact, talazoparib showed its superiority compared with chemotherapy in the survival and quality of life of patients with BRCA mutations, with an acceptable toxicity profile. While its role in this indication is not debated, its cost as well as the availability of other effective new agents, particularly immune checkpoint inhibitors, may encourage the movement of this drug to later treatment lines. Until more robust data are available, the best treatment sequence for BRCA-mutated breast cancer must be personalized on a case-by-case basis.

Keywords: BRCA mutation; PARP inhibitors; breast cancer; talazoparib.

Publication types

  • Review

MeSH terms

  • BRCA1 Protein / genetics
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / pathology
  • Female
  • Humans
  • Phthalazines / therapeutic use
  • Quality of Life

Substances

  • BRCA1 Protein
  • Phthalazines
  • talazoparib

Supplementary concepts

  • Breast Cancer, Familial